Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40

HONG KONG, Jan 29, 2021 – (ACN Newswire) – China Biotech Services Holdings Limited (“CH BIOTECH SER” or “Company”, stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( “Shanghai Longyao”), the Chief Scientist Professor Xuanming Yang published a CD20-CART-OX40 related research article on January 27, 2021, EST, on Science Translational Medicine. Professor Yang... » read more

China Biotech Services LY007 Cell Injection Obtained Clinical Trial Approval Letter

HONG KONG, Jan 28, 2021 – (ACN Newswire) – China Biotech Services Holdings Limited (“CH BIOTECH SER” or “Company”, stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( “Shanghai Longyao”) received an approval letter from the National Medical Products Administration for a clinical trial of the Company’s LY007 Cellular Injection on January 21,... » read more